https://www.swedenindustryinsider.com/article/913787994-cryotem-breaks-ground-as-new-method-added-to-u-s-pharmacopeia-s-updated-aav-reference-standard-certificates Sweden Industry Insider en PressRelease 2026-05-20T08:33:21+00:00 CryoTEM breaks ground as new method added to U.S. Pharmacopeia's updated AAV reference standard certificates https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24861972-usp-2699x2412.jpeg https://www.swedenindustryinsider.com/article/913810154-asko-introduces-scandinavian-laundry-care-2-0 Sweden Industry Insider en PressRelease 2026-05-20T09:17:10+00:00 ASKO Introduces Scandinavian Laundry Care 2.0 https://ml-eu.globenewswire.com/media/beb45551-04fb-4dab-8dd9-047071354130/medium/asko-scandinavian-laundry-care-2-0-titanium.jpg https://www.swedenindustryinsider.com/article/913810158-asko-presenterar-scandinavian-laundry-care-2-0 Sweden Industry Insider en PressRelease 2026-05-20T09:17:10+00:00 ASKO presenterar Scandinavian Laundry Care 2.0 https://ml-eu.globenewswire.com/media/beb45551-04fb-4dab-8dd9-047071354130/medium/asko-scandinavian-laundry-care-2-0-titanium.jpg https://www.swedenindustryinsider.com/article/913788145-serb-pharmaceuticals-erwirbt-von-hansa-biopharma-europ-ische-und-mena-rechte-an-idefirix-imlifidase-f-r-115-mio Sweden Industry Insider en PressRelease 2026-05-20T05:51:38+00:00 SERB Pharmaceuticals erwirbt von Hansa Biopharma europäische und MENA-Rechte an Idefirix® (Imlifidase) für 115 Mio. € https://ml.globenewswire.com/media/NGY2ZjhiYTAtYjMyMS00M2E4LWI2ODUtZjE5YmNiMTk5YTlhLTUwMDE1NTM3MC0yMDI2LTA1LTIwLWRl/tiny/SERB-Pharmaceuticals.png https://www.swedenindustryinsider.com/article/913788153-serb-pharmaceuticals-acquiert-aupr-s-de-hansa-biopharma-les-droits-europ-ens-et-mena-d-idefirix-imlifidase-pour-115-millions-d-euros Sweden Industry Insider en PressRelease 2026-05-20T05:51:38+00:00 SERB Pharmaceuticals acquiert auprès de Hansa Biopharma les droits européens et MENA d’Idefirix® (imlifidase) pour 115 millions d’euros https://ml.globenewswire.com/media/NGY2ZjhiYTAtYjMyMS00M2E4LWI2ODUtZjE5YmNiMTk5YTlhLTUwMDE1NTM3MC0yMDI2LTA1LTIwLWZy/tiny/SERB-Pharmaceuticals.png https://www.swedenindustryinsider.com/article/913562155-serb-pharmaceuticals-to-acquire-european-and-mena-rights-to-idefirix-imlifidase-from-hansa-biopharma-for-115-million Sweden Industry Insider en PressRelease 2026-05-19T05:30:00+00:00 SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million https://ml.globenewswire.com/media/7862df2f-dd67-489b-973a-030c1c164344/small/serb-rgb-trimmed-png.png